08/02/2012 3:28 am Welcome to isteroids.com - BLOG

Monday 19, Jul 2010

  Specific drugs identified for providing relief to patients to lung and joint ailments

Posted By

Specific drugs identified for providing relief to patients to lung and joint ailmentsA recent discovery by scientists at the University of Edinburgh will help patients afflicted with inflammatory conditions such as chronic diseases of the joints, lungs, and other organs get close to relief and reduced disease activity.

According to a new study in the Nature Medicine journal, specific drugs that have already been tested for cancer patients can reduce tissue inflammation by a significant extent.

From Sciencedaily.com:

The Edinburgh scientists have spent years devising ways of inducing apoptosis in specific inflammatory cells while, in parallel, driving macrophages to clear the resultant apoptotic cells more rapidly. Now they have shown that CDK inhibitors, like Roscovitine – which is already being tested in human cancer – are capable of inducing neutrophil apoptosis ‘in the test-tube’. Significantly, laboratory tests now suggest that they also reduce inflammation in models of rheumatoid arthritis and a devastating, currently untreatable, lung disease called fibrosing alveolitis.

Professor Chris Haslett, Head of the Queen’s Medical Research Institute at the University of Edinburgh, expects the study to lead to trials of these drugs in human inflammatory diseases. Professors Adriano Rossi and Haslett, who have led this new study with other colleagues from the QMRI, said: “This study offers new hope for patients with severe inflammatory diseases. Specific treatment for such conditions is poor, and the use of steroids is fraught with potential difficulties. We have adopted a different strategy by using non-biological treatments, but this study needs urgently to be translated into trials and we are now seeking major funding to research further how these drugs work.”

CDK inhibitors and many other specific non-biological drugs could be useful for knocking out the inflammatory cells behind damage to the tissue and scarring that often leads to organ failure and joint pain, as per the involved researchers.

Friday 09, Jul 2010

  Joint and lung diseases can be treated with potential cancer drugs

Posted By

Joint and lung diseases can be treated with potential cancer drugsAccording to a discovery by scientists at the University of Edinburgh as part of a study that was published in Nature Medicine journal, patients afflicted with inflammatory conditions such as chronic diseases of the joints, lung, and other organs can expect new ray of home.

The manner in which specific drugs, which are presently under the testing stage for curing cancer, can be used to considerably reduce the level of tissue inflammation was highlighted by the study.

From News-Medical.Net:

Professor Chris Haslett, Head of the Queen’s Medical Research Institute at the University of Edinburgh, expects the study to lead to trials of these drugs in human inflammatory diseases. Professors Adriano Rossi and Haslett, who have led this new study with other colleagues from the QMRI, said: “This study offers new hope for patients with severe inflammatory diseases. Specific treatment for such conditions is poor, and the use of steroids is fraught with potential difficulties. We have adopted a different strategy by using non-biological treatments, but this study needs urgently to be translated into trials and we are now seeking major funding to research further how these drugs work.”

It is important to note here that CDK inhibitors such as Roscovitine have the ability to reduce inflammtion level in the models of rheumatoid arthritis and the fatal ailment called fibrosing alveolitis, which is evident from lab tests in the past.

Wednesday 26, May 2010

  Potential cancer drug can help asthma patients

Posted By

Potential cancer drug can help asthma patientsR-roscovitine, a drug that is presently being tested for cancer, may prove for treating asthma as well, according to a research.

The drug can prove effective for killing certain immune cells capable of exacerbating symptoms associated with asthma, as per scientists at the University of Edinburgh.

From Sciencedaily.com:

Eosinophils, found in the lungs and airways, help the body fight off parasitic infection. However, too many uncontrolled eosinophils can damage other cells that line the lung, contributing to inflammatory conditions such as asthma.

Researchers found that use of the drug caused the eosinophil cells to undergo a form of cell death known as apoptosis, a natural process where unwanted cells are removed from the body.

Professor Adriano Rossi, of the Centre for Inflammation Research at the University of Edinburgh who directed the study, said: “Steroids are commonly used to treat asthma but can have unwanted side-effects, while some asthma patients are also resistant to steroid treatment. It may well be that use of a drug, such as R-Roscovitine, or one that works in a similar same way, could offer an alternative to steroids, or be used in conjunction with steroid treatment for asthma patients.”

The finding is expected to offer an alternative way for treating asthma in patients who show resistance to steroids that are commonly used and prescribed in asthma treatments.

Thursday 06, May 2010

  Prostate cancer progression can speed with hormonal nutritional supplements

Posted By

Prostate cancer progression can speed with hormonal nutritional supplementsAccording to a recent research, progression of prostate cancer and reduction in efficacy of anti-cancer drugs can be stimulated by hormonal components in over-the-counter dietary supplements.

This discovery by researchers at UT Southwestern Medical Center appeared in an issue of Clinical Cancer Research and reaffirmed that people visiting the doctors’ offices must inform them about any herbal or hormonal dietary supplements they are taking or considering taking.

From News-Medical.Net:

“Physicians need to ask their patients not only about the prescription drugs they may be taking, but – perhaps even more importantly – about the over-the-counter drugs and supplements, which may have a profound impact on certain health conditions,” said Dr. Claus Roehrborn, chairman of urology  at UT Southwestern and one of the study’s authors.

The researchers began their investigation when two patients being seen by UT Southwestern doctors developed aggressive prostate cancer within months of starting daily consumption of the same dietary supplement. Both men purchased the same product, one to develop stronger muscles and enhance sexual performance, the other to gain muscle.

Dr. Roehrborn, Dr. Shahrokh Shariat, a resident in urology and the study’s lead author, and their colleagues analyzed the supplement, which is not named in the study. They found that the product’s label listed ingredients that were not present, misrepresented the concentrations of the ingredients present and failed to list all the steroid hormones contained in the product.

It was recommended by the researchers that documentation of supplement use becomes part of routine health assessment for all patients, especially cancer patients.

Friday 23, Apr 2010

  New evidence suggest light therapy useful against fungal infections

Posted By

New evidence suggest light therapy useful against fungal infectionsAccording to Howard Hughes Medical Institute investigators at Duke University Medical Center, a recently discovered mechanism plays an important role in virulence of an infectious fungus.

It was suggested by the finding that light changes after fungal invasion of the human body could be an important and previously neglected cue that sparks infection as per the researchers.

From Sciencedaily.com:

The potentially life-threatening fungus C. neoformans invades the central nervous system to cause disease, most commonly in patients who lack a functioning immune system, such as organ transplant recipients, those with HIV/AIDS, and patients treated with steroids or cancer chemotherapy. The fungus’ global importance as a health threat has therefore risen in parallel with the increase in immunosuppressive therapies and the worldwide HIV/AIDS epidemic.

Light normally inhibits mating of C. neoformans. The Duke team has now identified two genes responsible for that light response. Loss of the same genes also reduces fungal virulence in mice, they reported.

Earlier studies had linked the genes to light-sensing in another distantly related fungal lineage, an indication that the fungal light sensor arose early in evolution and may be shared by many extant fungal species. Other well-studied fungi, such as Saccharomyces cerevisiae, or baker’s yeast, have apparently lost their ability to sense light, Heitman said, and have neither of the conserved light-sensing proteins.

“Fungi have many negative implications for human life as they lead to human disease, as well as plant disease and mold,” said Idnurm, a post-doctoral fellow at Duke. “However, fungi also play important beneficial roles, for example, as a source of food and pharmaceuticals.

HHMI investigator Joseph Heitman, M.D., James B. Duke professor of molecular genetics and microbiology and medicine at Duke, said that light therapy can provide an effective method for combating against a variety of fungal infections when combined with anti-fungal treatments.

Wednesday 21, Apr 2010

  Skin rash signifies improved outcomes for lung and pancreatic cancer patients

Posted By

Skin rash signifies improved outcomes for lung and pancreatic cancer patientsThe appearance of a rash in patients suffering from cancer and treated with erlotinib (Tarceva) is strongly associated with longer survival, as per researchers from the drug’s developer, OSI Pharmaceuticals, Inc.

This is not the first time that rashes have been linked with a survival advantage in regard to a class of drugs, EGFR (epidermal growth factor receptor) inhibitors, which include erlotinib, cetuximab, panitumumab and others designed for blocking overproduction of EGFR but this was hailed as the most detailed analysis to date.

From Sciencedaily.com:

According to the researchers, these rashes can be controlled with mild steroids or antibiotics, and in most cases, they will improve with treatment. They are believed to be due to an inflammatory response as a result of EGFR inhibition in skin tissue, Wacker said.

The analysis looked at two placebo-controlled, double-blind, randomized, Phase III clinical trials testing Tarceva in advanced non-small cell lung cancer and pancreatic cancer - studies which led to approval of the agent for treating both cancers. Wacker and his team excluded patients who died in the first month after starting the study because they may not have had time to develop the rash or the rash may have been under-reported in these ill patients.

The study was published in the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.

Monday 19, Apr 2010

  Preemptive treatment helps in preventing skin toxicity with Panitumumab

Posted By

Preemptive treatment helps in preventing skin toxicity with PanitumumabPatients receiving panitumumab for treating metastatic colorectal cancer can avoid some of the skin-associated toxicities with a preemptive and prophylactic skin regimen, as per data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study that was the first prospective study for comparing preemptive and reactive skin treatment for skin toxicities related to panitumumab.

From News-Medical.Net:

The researchers studied 95 patients receiving panitumumab in combination with irinotecan-based chemotherapy. The patients were randomized to receive pre-emptive skin toxicity treatment initiated 24 hours prior to the first dose of panitumumab, then given daily through week six, or reactive skin treatment after the skin toxicity developed. The skin treatment included moisturizers, sunscreen, topical steroids and oral doxycycline.

The primary endpoint was the incidence of specific grade 2 or higher skin toxicities during the six week skin treatment period. The incidence of these toxicities was reduced more than 50% in the group that received pre-emptive treatment.

Quality of life was also assessed, using the Dermatology Life Quality Index. Patients who received the pre-emptive, prophylactic skin treatment regimen reported an improved quality of life, even around week three, which was the median time to first grade 2 or higher skin toxicity in the reactive skin treatment group.

The study was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University‘s Feinberg School of Medicine in Chicago.

Wednesday 14, Apr 2010

  Patients suffering from lupus get relief with Rituximab

Posted By

Patients suffering from lupus get relief with RituximabRituximab, which is currently indicated to patients suffering from cancer, can also prove effective for providing relief to patients with lupus and suffering from complications of the central nervous system, as per rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria.

Lupus is an immune system disorder that characterizes an attack by the human body on itself leading to diffused damage to several body organs besides resulting in inflammation and pain.

From News-Medical.Net:

Professor Neuwelt specialises in diagnosing and treating patients with CNS lupus. “It can be difficult to disentangle psychiatric disorders that arise from other causes,” he states. In a portion of patients, depression, seizures, verbal comprehension, perception and memory will be associated with lupus. People are understandably afraid to admit that their IQ has gone down or that they cannot read any more in fear of losing their job,” he continued. A careful history, ruling out other causes such as infection and drug side effects has improved diagnostic accuracy.

Professor Neuwelt, like others using this well-tested oncological drug in other forms of lupus, is concerned about the depletion of the B cells by rituximab for the long term. However, the risk/benefit ratio from this new treatment in its early stages is extremely promising. “It is the first drug in my 26 years of treating patients with severe central nervous system lupus, used alone or in combination with other therapies that has not only significantly boosted the quality of life for patients with this dreadful disease, but also reduced the burden of side effects of standard treatment with steroids and cyclophosphamide. However, we desperately need randomized-controlled trials.” he concluded.

Clinical professor Michael Neuwelt, at the University of California San Francisco and Stanford University, said that Rituximab proves effective and may be classified as a gentler treatment form, which can last up to six months with a low risk of any side effect.

Wednesday 07, Apr 2010

  Steroid pills provide considerable relief to multiple myeloma patients

Posted By

Steroid pills provide considerable relief to multiple myeloma patientsTreatment of multiple myeloma, a dreadful type of cancer, with steroid pills is an effective form of treatment for improving the overall survival rate of patients, as per researchers at the Cedars-Sinai Medical Center.

Multiple myeloma is a cancer of the plasma cells in the bone marrow that is believed to claim approximately 14,000 lives annually in the United States alone.

From News.Bio-Medicine.Org:

Multiple myeloma occurs when the body makes an abnormally high number of cancerous plasma cells. When healthy, plasma cells help to protect the body from infection and disease by forming antibodies that attack foreign substances. But when the body makes too many plasma cells that all make the same type of antibody, this leads to multiple myeloma, causing damage to bones, severe bone pain, an overabundance of calcium in the blood, anemia, and a weakening of the immune system. Today, most patients with multiple myeloma receive initial treatment with chemotherapy or with high-dose chemotherapy followed by a stem cell transplant and many respond to treatment and achieve remission. However, all patients ultimately relapse with incurable disease, leading physicians to search for ways to prolong remission for as long as possible by using some type of maintenance therapy.

James Berenson, M.D., lead author of the Southwest Oncology Group sponsored study and Director of the Multiple Myeloma and Bone Metastasis Program at Cedars-Sinai Medical Center, remarked that use of prednisone in response to an upfront chemotherapy can be classified as safe and effective for treating patients suffering from multiple myeloma.

Tuesday 23, Mar 2010

  R-Roscovitine useful for exacerbating asthma symptoms

Posted By

R-Roscovitine useful for exacerbating asthma symptomsScientists at the University of Edinburgh recently found that a drug presently under the testing stage for treating cancer may prove to be a useful option for providing relief to patients with asthma.

The drug, R-Roscovitine, is effective in killing specific immune cells that may exacerbate asthma-associated symptoms.

From News-Medical.Net:

Eosinophils, found in the lungs and airways, help the body fight off parasitic infection. However, too many uncontrolled eosinophils can damage other cells that line the lung, contributing to inflammatory conditions such as asthma.

Researchers found that use of the drug caused the eosinophil cells to undergo a form of cell death known as apoptosis, a natural process where unwanted cells are removed from the body.

Professor Adriano Rossi, of the Centre for Inflammation Research at the University of Edinburgh who directed the study, said: “Steroids are commonly used to treat asthma but can have unwanted side-effects, while some asthma patients are also resistant to steroid treatment. It may well be that use of a drug, such as R-Roscovitine, or one that works in a similar same way, could offer an alternative to steroids, or be used in conjunction with steroid treatment for asthma patients.”

This finding is expected to provide an alternative way for treating asthmatic patients who show resistance to steroids.

Next »